Anesiva, Inc. Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger
Published: Nov 23, 2009
SOUTH SAN FRANCISCO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Anesiva, Inc. today announced that Dr. Ted W. Love and Dr. David C. U'Prichard have agreed to join the Anesiva board of directors following completion of the proposed merger between Anesiva and Arcion Therapeutics. Completion of the merger is subject to a shareholder vote scheduled to take place at the previously announced Anesiva 2009 Annual Meeting of Stockholders, to be held on December 3, 2009 at 9:00 a.m. PST at 400 Oyster Point, Suite 107A, South San Francisco, California, among other conditions.
"Maintaining governance requirements and a qualified NASDAQ listing is a high priority for the merged companies and these gentlemen will bring excellent experience to our board," said Dr. Arnold Oronsky, director of Anesiva and Arcion Therapeutics.
Dr. U'Prichard currently serves as president of Druid Consulting LLC and as a venture partner at Red Abbey Venture Partners. Previously, he was chief executive officer of 3-Dimensional Pharmaceuticals (3DP) from 1999 to 2003. From 1997 to 1999, Dr. U'Prichard served as chairman of research and development at SmithKline Beecham Pharmaceuticals. Prior to SmithKline Beecham, he worked for ICI/Zeneca from 1986 to 1997, as executive vice president and International Research Director from 1994 to 1997. He is currently a member of the board of directors of Life Technologies and Silence Therapeutics Plc, and chairman of Cyclacel, Inc. and Oxagen Ltd. Dr. U'Prichard received his Ph.D. from the University of Kansas and his B.Sc. from the University of Glasgow, Scotland.
Anesiva seeks to be a leader in the development and commercialization of novel pharmaceutical products for pain management. Anesiva's lead product candidate is Adlea, a novel small molecule formulation of capsaicin that is currently in development for the management of acute pain following orthopedic surgeries. Adlea has been shown in clinical trials to provide extended pain relief after only a single administration in multiple indications for site-specific, acute and chronic, moderate-to-severe pain.
Arcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on innovative topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's product pipeline comprises multiple candidates to treat neuropathic pain.
Anesiva has a filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") in connection with the 2009 Annual Meeting of Stockholders. Investors and security holders are urged to read the definitive proxy statement because it contains important information about the 2009 Annual Meeting of Stockholders. Investors and security holders may obtain free copies of this document and other documents filed with the SEC at the SEC's website at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Anesiva by contacting John Tran at 650-624-9600.
CONTACT: John Tran, +1-650-624-9600, for Anesiva, Inc.
Web site: http://www.anesiva.com/